Literature DB >> 30659691

Impact of tumor-associated macrophages and BRAFV600E mutation on clinical outcomes in patients with various thyroid cancers.

Jae Won Cho1, Won Woong Kim1, Yu-Mi Lee1, Min Ji Jeon2, Won Gu Kim2, Dong Eun Song3, Yangsoon Park3, Ki-Wook Chung1, Suck Joon Hong1, Tae-Yon Sung1.   

Abstract

BACKGROUND: Tumor-associated macrophages (TAMs) play a role in thyroid cancer tumor progression and metastasis. This study aimed to investigate the association of TAM density and cluster of differentiation 68 (CD68) expression with thyroid tumors as a prognostic marker and the relationship of these factors with BRAFV600E mutations.
METHODS: This study included 275 thyroid specimen tissues, including benign and malignant lesions. We compared the clinicopathological features according to thyroid tumor types and evaluated the presence of CD68 expression and BRAFV600E mutations.
RESULTS: CD68 positive expression increased with aggressiveness of thyroid tumor histologic grades (P < 0.001). In patients with poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), CD68 positivity was associated with aggressive adverse clinical outcomes such as extrathyroidal extension, cervical lymph node metastases, and distant metastases (P < 0.05).
CONCLUSIONS: CD68 positivity was more frequent in advanced and aggressive thyroid cancer types such as PDTC/ATC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAFV600E mutation; CD68; prognosis; thyroid cancer; tumor-associated macrophages

Year:  2019        PMID: 30659691     DOI: 10.1002/hed.25469

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1. 

Authors:  茜璇 卢; 黎莎 包; 宗富 潘; 明华 葛
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

Review 2.  Immunotherapy for anaplastic thyroid carcinoma: the present and future.

Authors:  Xixuan Lu; Lisha Bao; Zongfu Pan; Minghua Ge
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

3.  Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.

Authors:  Jinyan Chai; Ruiguo Zhang; Wei Zheng; Guizhi Zhang; Qiang Jia; Jian Tan; Zhaowei Meng; Renfei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

4.  MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.

Authors:  Yanhua Yang; Shujun Xia; Lu Zhang; Wenhan Wang; Lin Chen; Weiwei Zhan
Journal:  Cancer Biol Ther       Date:  2020-03-10       Impact factor: 4.742

Review 5.  The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.

Authors:  Gilda Varricchi; Stefania Loffredo; Giancarlo Marone; Luca Modestino; Poupak Fallahi; Silvia Martina Ferrari; Amato de Paulis; Alessandro Antonelli; Maria Rosaria Galdiero
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

6.  Potential role of M2 TAMs around lymphatic vessels during lymphatic invasion in papillary thyroid carcinoma.

Authors:  Takanobu Kabasawa; Rintaro Ohe; Naing Ye Aung; Yuka Urano; Takumi Kitaoka; Nobuyuki Tamazawa; Aya Utsunomiya; Mitsunori Yamakawa
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 7.  Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis.

Authors:  Veronica Veschi; Francesco Verona; Melania Lo Iacono; Caterina D'Accardo; Gaetana Porcelli; Alice Turdo; Miriam Gaggianesi; Stefano Forte; Dario Giuffrida; Lorenzo Memeo; Matilde Todaro
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-25       Impact factor: 5.555

8.  Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Jian Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.